Skip to main content

Table 5 Clinical characteristics of ALL patients of known and newly classified subtype

From: DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia

Subtype N (%) a Sex M:F Age median (range) WBC median (range) CNS, b n/y/u CIR c NOPHO protocol d EsPhALL e Infant f Other/NA g
SR IR HR Ph+
T-ALL 101 (0.18) 2.9 9 (1–17) 138 (1–788) 89/12/0 0.20 0 2 86 1 0 0 12
T-ALL* 1 (0.00) NA 11 (NA) 2 (NA) 1/0/0 0.00 0 0 1 0 0 0 0
HeH 189 (0.35) 1.2 3 (1–17) 9 (0–131) 187/2/0 0.16 82 79 22 0 0 0 6
HeH* 25 (0.12) 2.1 4 (1–14) 9 (1–91) 24/1/0 0.28 8 10 3 0 0 0 4
t(12;21) 161 (0.29) 1.1 4 (1–15) 14 (1–226) 159/0/2 0.22 68 65 24 0 0 0 4
t(12;21)* 33 (0.16) 1.1 4 (0–15) 11 (1–136) 33/0/0 0.24 12 11 6 0 0 1 3
11q23/MLL 27 (0.05) 0.7 0 (0–15) 193 (2–986) 25/1/0 0.41 0 1 11 0 0 14 1
11q23/MLL* 4 (0.02) 4.0 1 (0–1) 81 (38–1,255) 4/0/0 0.50 0 1 2 0 0 1 0
t(1;19) 21 (0.04) 0.8 11 (1–15) 35 (6–159) 20/1/0 0.14 0 3 17 0 0 0 1
t(1;19)* 15 (0.07) 0.9 7 (1–15) 10 (5–222) 14/1/0 0.07 1 9 3 0 0 0 2
dic(9;20) 20 (0.04) 0.4 2 (1–15) 50 (4–336) 19/1/0 0.25 4 5 10 0 0 0 1
dic(9;20)* 19 (0.09) 1.7 4 (1–18) 12 (1–164) 19/0/0 0.21 3 11 2 0 0 0 3
t(9;22) 19 (0.03) 2.2 10 (2–14) 61 (3–246) 17/2/0 0.47 0 0 1 6 12 0 0
t(9;22)* 5 (0.02) 4.0 12 (4–15) 102 (13–146) 5/0/0 0.40 0 0 1 0 0 0 4
iAMP21 8 (0.01) 7.0 9 (5–17) 5 (2–62) 8/0/0 0.38 2 3 1 0 0 0 2
iAMP21* 4 (0.02) 0.3 9 (7–16) 9 (4–23) 4/0/0 0.50 1 2 0 0 0 0 1
Multi-class 17 (0.03) 0.9 10 (3–17) 23 (1–106) 16/1/0 0.06 1 6 2 0 0 0 8
Non-class 83 (0.15) 1.5 9 (0–18) 20 (1–274) 80/3/0 0.23 13 30 25 0 0 3 11
  1. *Patients with subtype determined by DNA methylation-based classification.
  2. aProportion of the total number of patients in the known subtype groups (n = 546) and newly classified patients (n = 210).
  3. bCentral nervous system involvement.
  4. cCumulative incidence of relapse (relapse as event of interest and other events as censoring).
  5. dNumber of patients treated on NOPHO-ALL treatment protocols.
  6. eNumber of patients treated according to the EsPhALL protocol.
  7. fNumber of patients treated according to the Interfant-99 or Interfant-06 protocols.
  8. gNumber of patients treated on other protocol or information not available.
  9. Abbreviations: WBC white blood cell count at diagnosis, n/y/u no/yes/unknown, SR standard risk, IR intermediate risk, HR high risk, Ph + Philadelphia positive.